title: Successful salvage therapy with Daptomycin for osteomyelitis caused by methicillin-resistant Staphylococcus aureus in a renal transplant recipient with Fabry-Anderson disease.
abstract: Daptomycin is licensed in adults for the management of Staphylococcus aureus methicillin-resistant infections, including bone and skin complicated infections. We describe for the first time its use in a renal transplant recipient for Fabry-Anderson Disease with right heel osteomyelitis. The patient was unresponsive to first-line Teicoplanin and second-line Tigecycline, whereas he was successfully treated with third-line Daptomycin monotherapy at 4 mg/Kg/qd for 4 weeks. Local debridement was performed in advance of each line of treatment.
authors.affiliation: Microbiology and Virology Unit, Pescara General Hospital, Pescara, Italy.
authors.forename: Ennio
authors.initials: E
authors.lastname: Polilli
authors.forename: Tamara
authors.initials: T
authors.lastname: Ursini
authors.forename: Elena
authors.initials: E
authors.lastname: Mazzotta
authors.forename: Federica
authors.initials: F
authors.lastname: Sozio
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Savini
authors.forename: Domenico
authors.initials: D
authors.lastname: D'Antonio
authors.forename: Michelino
authors.initials: M
authors.lastname: Barbato
authors.forename: Augusta
authors.initials: A
authors.lastname: Consorte
authors.forename: Giustino
authors.initials: G
authors.lastname: Parruti
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D000890:Anti-Infective Agents / Q000627:therapeutic use; D002111:Calcaneus / Q000293:injuries / Q000382:microbiology; D017576:Daptomycin / Q000008:administration & dosage*; D000795:Fabry Disease / Q000150:complications*; D006365:Heel / Q000000981:diagnostic imaging / Q000382:microbiology; D006801:Humans; D016030:Kidney Transplantation; D008297:Male; D016106:Methicillin Resistance; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects*; D008795:Metronidazole / Q000627:therapeutic use; D008911:Minocycline / Q000031:analogs & derivatives / Q000627:therapeutic use; D010019:Osteomyelitis / Q000150:complications / Q000188:drug therapy*; D051437:Renal Insufficiency; D016879:Salvage Therapy; D013203:Staphylococcal Infections / Q000150:complications / Q000188:drug therapy*; D017334:Teicoplanin / Q000627:therapeutic use; D000078304:Tigecycline; D014057:Tomography, X-Ray Computed
chemical_list: D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D008795:Metronidazole; D017334:Teicoplanin; D000078304:Tigecycline; D008911:Minocycline; D017576:Daptomycin